Steven Elms

Steven Elms

Presidente presso ADMA BIOLOGICS, INC.

Patrimonio netto: 701 553 $ in data 31/05/2026

62 anni
Health Technology
Finance
Health Services

Profilo

Steven Arnote Elms is currently Chairman at ADMA Biologics, Inc. since 2012.
He is an Independent Director at Marker Therapeutics, Inc. since 2019 and serves on the Board of Directors at Ajax Health LLC.
He is Director at Marker Cell Therapy, Inc. since 2019, Director at Ajax Health II LLC, Director at Treeline Biosciences, Inc., Managing Partner at Aisling Capital LLC since 2000, Managing Member at Aisling Capital Partners LLC, and Member-INVO Board at Northwestern University.
Former positions include Chairman at MAP Pharmaceuticals LLC from 2004 to 2011, Co-Chairman at LENSAR, Inc., Chairman at Adams Respiratory Therapeutics, Inc. from 2001 to 2006, Chairman at Oculex Pharmaceuticals, Inc., Chairman at Elevation Oncology, Inc. from 2020 to 2025, Director at Bioenvision, Inc. from 2002 to 2007, Director at Advion BioSciences, Inc., Director at Avera Pharmaceuticals, Inc. from 2004 to 2013, Director at Ambit Biosciences Corp.
from 2001 to 2014, Independent Director at TRIA Beauty, Inc. from 2012 to 2013, Director at CeNeRx BioPharma, Inc., Director at NextWave Pharmaceuticals, Inc., Director at Earlens Corp., Director at Advion, Inc., Director at Novazyme Pharmaceuticals, Inc., Director at Medical Knowledge Group LLC, Director at Scerene Healthcare, Inc., Director at Archimica Cooperatief UA, Independent Non-Executive Director at Pernix Therapeutics Holdings, Inc. from 2011 to 2016, Independent Director at Zosano Pharma Corp.
from 2018 to 2022, Independent Director at Loxo Oncology, Inc. from 2013 to 2019, Independent Director at Cidara Therapeutics, Inc. from 2014 to 2015, Principal at Hambrecht & Quist Group, Consultant at Wilkerson Group, Principal at Marion Laboratories, and Principal-Life Sciences Investment Banking Group at Hambrecht & Quist.
Education includes undergraduate studies at Stanford University and an MBA from Kellogg School of Management.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValutazioneData di valutazione
31/03/2026 87.330 ( 0,04% ) 696 893 $ 31/05/2026
01/03/2026 2.968 ( 0,02% ) 4 660 $ 31/05/2026

Posizioni attive di Steven Elms

SocietàPosizioneInizio
ADMA BIOLOGICS, INC. Presidente 30/03/2012
MARKER THERAPEUTICS, INC. Direttore/Membro del Consiglio 06/08/2019
Aisling Capital Partners LLC
Corporate Officer/Principal -
Direttore/Membro del Consiglio 06/08/2019
Corporate Officer/Principal -
Direttore/Membro del Consiglio -
Direttore/Membro del Consiglio -
Direttore/Membro del Consiglio -
Investitore di Private Equity 01/07/2000

Precedenti posizioni note di Steven Elms

SocietàPosizioneFine
░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░ ░░░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di Steven Elms

Formazione di Steven Elms

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

59

Relazioni di 1° grado

37

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private37

Finance

Health Services

Health Technology

Commercial Services

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Aisling Capital Partners LLC

Health Technology

Health Technology

Consumer Services

Commercial Services

Health Services

Health Technology

Consumer Services

Distribution Services

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Hambrecht & Quist

Finance

Commercial Services

Finance

Health Technology

Health Technology

  1. Mercati
  2. Insiders
  3. Steven Elms
- 40%: I migliori strumenti riservati agli abbonati per individuare le opportunità di investimento di domani.
g
:
:
ENTRA ORA